argenx vs Edwards Lifesciences
argenx (ARGX), health care, and Edwards Lifesciences (EW), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.
Edwards Lifesciences is worth $61.8B on the stock market and argenx $59.4B: Edwards Lifesciences is valued at 4% more. argenx trades at 32.7 times earnings and Edwards Lifesciences at 62.5; operating margins in their latest fiscal years were 25.4% and 20.8%. Over the past year argenx's share price has moved +3.53% and Edwards Lifesciences's +27.5%.
Key facts
- argenx market value
- $59.4B
- Edwards Lifesciences market value
- $61.8B
- argenx P/E
- 32.7
- Edwards Lifesciences P/E
- 62.5
- argenx revenue
- $4.2BFY to 2025-12-31
- Edwards Lifesciences revenue
- $6.1BFY to 2025-12-31
- Superinvestors holding both
- 1
Market values as of .
| Measure | argenx | Edwards Lifesciences |
|---|---|---|
| Sector | Health Care | Health Care |
| Country | ||
| Fiscal year ends | 2025-12-31 | 2025-12-31 |
| Size | ||
| Market cap | $59.4Blower | $61.8Bhigher |
| Revenue | $4.2Blower | $6.1Bhigher |
| Earnings | $1.3Bhigher | $1.1Blower |
| Employees | 1,863lower | 16,000higher |
| Total assets | $8.7Blower | $13.7Bhigher |
| Valuation | ||
| P/E | 32.7lower | 62.5higher |
| P/S | 14.3higher | 10.2lower |
| P/B | — | 5.7 |
| Dividend yield | — | 0.00% |
| Profitability | ||
| Operating margin | 25.4%higher | 20.8%lower |
| Balance sheet | ||
| Net assets | $7.3Blower | $10.3Bhigher |
| Total liabilities | $1.4Blower | $3.4Bhigher |
| Total debt | — | $598.3M |
| Cash on hand | $3.5Bhigher | $2.9Blower |
| Price change | ||
| Today | -0.62%lower | +0.29%higher |
| 1 year | +3.53%lower | +27.5%higher |
Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.
Which superinvestors hold them
From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.
Both (1)
- Ron Baron0.2% / 0.1%
argenx only (1)
- Frank Sands1.0%
Edwards Lifesciences only (8)
- David Rolfe3.1%
- Howard Gleicher1.6%
- Brandon Haley0.7%
- Steve Cohen0.2%
- Israel Englander0.2%
- Ken Griffin0.2%
- Primecap team0.2%
- Baillie Gifford team0.1%
Percentages are each holding's share of that investor's reported portfolio (under "Both": argenx / Edwards Lifesciences). Who owns ARGX · Who owns EW
More on argenx
Further comparisons
argenx against its closest peers
Edwards Lifesciences against its closest peers
Learn
Questions and answers
Which is bigger, argenx or Edwards Lifesciences?
By market value, Edwards Lifesciences is the larger: $61.8B against $59.4B for argenx. By revenue in its latest fiscal year, Edwards Lifesciences is the larger: $6.1B against $4.2B for argenx.
Which has the higher P/E ratio?
Edwards Lifesciences: 62.5, against 32.7 for argenx. A higher P/E means the market pays more for each dollar of the last twelve months' earnings; on its own it does not say which is the better value.
Which has the higher operating margin?
argenx: 25.4%, against 20.8% for Edwards Lifesciences. Operating margin is operating income as a share of revenue in the latest fiscal year.
Which superinvestors own both argenx and Edwards Lifesciences?
In their latest 13F filings, Ron Baron holds both.
Cite this page
Funkfolio, “argenx vs Edwards Lifesciences”, data as of 17 November 2026. https://funkfolio.com/compare/argx-vs-ew
Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.